Browsing Tag
JNJ
3 posts
Johnson & Johnson shows new TECNIS PureSee data at ASCRS 2026 as JNJ eyes deeper ophthalmology upside
Johnson & Johnson unveiled new TECNIS PureSee data at ASCRS 2026. Read how it could reshape cataract surgery growth and JNJ’s medtech outlook.
April 11, 2026
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
February 27, 2026
Johnson & Johnson announces $13.1bn acquisition of Shockwave Medical to strengthen medtech division
In a monumental move within the medical technology sector, Johnson & Johnson (NYSE: JNJ) has announced its acquisition…
April 8, 2024